Fu, Accalia
Alvarez-Perez, Juan Carlos
Avizonis, Daina
Kin, Tatsuya http://orcid.org/0000-0002-5179-6067
Ficarro, Scott B.
Choi, Dong Wook
Karakose, Esra
Badur, Mehmet G.
Evans, Lindsay
Rosselot, Carolina
Bridon, Gaelle
Bird, Gregory H.
Seo, Hyuk-Soo http://orcid.org/0000-0003-0646-2102
Dhe-Paganon, Sirano
Kamphorst, Jurre J.
Stewart, Andrew F.
James Shapiro, A. M.
Marto, Jarrod A. http://orcid.org/0000-0003-2086-1134
Walensky, Loren D. http://orcid.org/0000-0002-0869-2334
Jones, Russell G.
Garcia-Ocana, Adolfo
Danial, Nika N. http://orcid.org/0000-0003-4842-1827
Funding for this research was provided by:
JDRF (2-SRA-2015-58-Q-R)
Terry Fox Foundation (Oncometabolism Team Grant 1048)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01DK078081, R01CA219850, R01DK116873)
U.S. Department of Health & Human Services | National Institutes of Health (R50CA211399, R01DK105015, R01CA222218, R01CA219850, R35CA197583, R01DK113079)
Article History
Received: 31 January 2020
Accepted: 26 March 2020
First Online: 11 May 2020
Competing interests
: J.A.M. serves on the SAB of 908 Devices, and has received sponsored research support from AstraZeneca and Vertex. L.D.W. is a scientific co-founder and shareholder in Aileron Therapeutics. R.G.J. is a scientific advisory board member for Immunomet Therapeutics and consultant for Agios Pharmaceuticals. All other authors declare no competing interests.